Fennec up on study testing expanded use of its hearing‑loss prevention drug in cancer patients

Fennec Pharmaceuticals

07/04/2026 12:51

** Shares of drugmaker Fennec Pharmaceuticals FENC.O rise 2% to $6.54 premarket

** Co says a new study has begun testing its drug PEDMARK for prevention of hearing loss in adolescent, young adult and adult patients treated with cisplatin

** Cisplatin is a common chemotherapy drug that can cause permanent hearing damage

** Co says the drug is already approved in the U.S. for children with localized solid tumors and backed by cancer treatment guidelines for adolescent and young adult patients

** Study will track whether PEDMARK lowers hearing impairment in adult patients with head and neck and testicular cancers, and how it affects removal of cisplatin from the body - FENC

** Says it is discussing plans with regulators to expand the drug’s label to more patient groups

** As of last close, stock down ~17% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))